ALPHA1 ANTITRYPSIN DEFICIENCY
Clinical trials for ALPHA1 ANTITRYPSIN DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new ALPHA1 ANTITRYPSIN DEFICIENCY trials appear
Sign up with your email to follow new studies for ALPHA1 ANTITRYPSIN DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug could slow liver damage in rare genetic disease
Disease control Recruiting nowThis study tests an experimental drug called fazirsiran in 160 adults with Alpha-1 antitrypsin deficiency who have moderate to severe liver scarring. The goal is to see if fazirsiran can reduce fibrosis and slow disease progression compared to a placebo. Participants will receive…
Matched conditions: ALPHA1 ANTITRYPSIN DEFICIENCY
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug aims to stop liver scarring in Alpha-1 patients
Disease control Recruiting nowThis study tests a medicine called fazirsiran for people with Alpha-1 antitrypsin deficiency who already have mild liver scarring. The drug works by reducing the buildup of an abnormal protein in the liver that causes damage. About 50 participants will receive either fazirsiran o…
Matched conditions: ALPHA1 ANTITRYPSIN DEFICIENCY
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
500 adults to help unravel mysteries of rare liver disease
Knowledge-focused Recruiting nowThis study follows 500 adults with alpha-1 antitrypsin deficiency (AATD) for up to 5 years to see how their liver disease progresses without any special treatment. Researchers will track changes in liver scarring, symptoms, and overall health using medical records and yearly ques…
Matched conditions: ALPHA1 ANTITRYPSIN DEFICIENCY
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC